MMP9 and early-onset autosomal dominant Alzheimer disease: There has recently been considerable interest in the proinflammatory Cyclophilin A–matrix metalloproteinase-9 (CypA–MMP9) pathway as a potential drug target for the treatment of Alzheimer’s disease (AD)1.